FDA approves a CRISPR-based medicine for treatment of sickle cell disease; A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

Taking stock of the drug industry, from the lab to the medicine chest

December 8, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Christine Kao/STAT In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease The groundbreaking treatment, for sickle cell disease, is called Casgevy and was developed by Vertex and CRISPR Therapeutics. By Adam Feuerstein STAT+ | A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead The chief executive of CRISPR Therapeutics sits down for a conversation about a historic approval and the road ahead. By Adam Feuerstein STAT+ | Vertex gets a win as Colorado board leaves cystic fibrosis drug off a list of unaffordable medicines The Colorado board decision "likely sets a precedent" that could benefit other companies with orphan drugs, one Wall Street analyst predicted. By Ed Silverman Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser